A Phase 1 Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors
What is the purpose of this trial?
The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1948 and determine the recommended Phase 2 dose (RP2D) of ASP1948. This study will also evaluate the antitumor effect of ASP1948.
- Trial withAstellas Pharma US, Inc.
- Start Date10/30/2018
- End Date03/27/2021
- Last Updated07/07/2020
- Study HIC#2000023045